OCT devices hold promise

Article

Improved imagery could help physicians learn more about diseases and treatment response

New optical coherence tomography (OCT) devices are in development with the goal of expanding the utility of OCT in the clinic by providing better resolution, faster speed, and software to help clinicians better understand the nuances of diseases and how they respond to therapy. Dr Jay S. Duker looked at the past, present and future of the technology during the Retina Subspeciality Day at the annual meeting of the American Academy of Ophthalmology.

The first OCTs that became commercially available in 1996 were time-domain (TD) instruments. Those reached their pinnacle in 2002 when the Stratus OCT was introduced by Zeiss. That instrument, which had 10 μm axial resolution and obtained 400 axial scans per second, remained the state-of-the-art technology until recently.

Over the past decade, many new OCT instruments have become available that are all based on Fourier-domain detection. Spectral-domain (SD) OCT became commercially available in 2006 and swept-source OCT is being used in research but is not yet commercially available. SD-OCT is faster than TD-OCT and can obtain from 20000 to 52000 scans per second. It also has a broader band width that increases the axial resolution from 4 to 7 μm.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.